Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a hold rating and eighteen have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $294.50.

Several equities analysts have issued reports on ALNY shares. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Citigroup raised their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday. Finally, Chardan Capital reiterated a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. The trade was a 16.96 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently bought and sold shares of ALNY. Capital Research Global Investors grew its holdings in Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after purchasing an additional 214,908 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after acquiring an additional 201,784 shares during the last quarter. Eventide Asset Management LLC increased its holdings in Alnylam Pharmaceuticals by 157.9% during the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock valued at $61,698,000 after acquiring an additional 137,333 shares in the last quarter. Los Angeles Capital Management LLC raised its position in Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after acquiring an additional 135,829 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 92.5% in the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock valued at $65,862,000 after purchasing an additional 130,482 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $235.56 on Friday. The stock’s 50-day simple moving average is $274.95 and its 200-day simple moving average is $234.30. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The firm has a market capitalization of $30.38 billion, a PE ratio of -89.91 and a beta of 0.39. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same period in the previous year, the company earned $1.15 EPS. The company’s revenue was down 33.3% on a year-over-year basis. As a group, equities research analysts forecast that Alnylam Pharmaceuticals will post -2.22 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.